logo
Orcas make seaweed tools to scratch each other's backs, study suggests

Orcas make seaweed tools to scratch each other's backs, study suggests

Yahoo23-06-2025
Orcas make seaweed tools in order to scratch each other's backs, a study has suggested.
The animals, also known as killer whales, were observed detaching lengths of seaweed and massaging each other with it.
The orcas bite off the end of a kelp stalk, position it between themselves and a partner, and roll the kelp between their bodies for prolonged periods, researchers said.
The study was led by the Centre for Whale Research (CWR), in collaboration with the University of Exeter.
The paper, published in the journal Current Biology, is entitled: 'Wild killer whales manufacture and use allogrooming tools.'
Scientists spotted the behaviour in drone footage of southern resident orcas in the Salish Sea, in the inland waters of the US state of Washington.
Whales of all ages were seen partaking in the tool-making, possibly to strengthen social bonds and promote skin health, researchers suggested.
CWR research director Dr Michael Weiss said researchers were 'amazed' when they first noticed the behaviour.
Several whale species are known to engage in 'kelping' – moving kelp with their heads, fins and bodies – likely for play, or possibly to remove parasites and maintain healthy skin.
The new discovery, dubbed 'allokelping', is different because the kelp is selected, trimmed and manipulated by two whales working together.
Dr Weiss added: 'Bull kelp stalk is firm but flexible, like a filled garden hose, with a slippery outer surface. I suspect these features make it an ideal grooming tool.
'What I find remarkable about this behaviour is just how widespread it is in the population.
'Males and females of all life stages and from all three southern resident pods were seen using kelp in this way. All evidence points to it being an important part of their social lives.'
The team observed allokelping on eight out of 12 days included in the study and based on their observations, suspect that this behaviour may be universal in this population.
Whales were most likely to pair up to allokelp with close maternal relatives, and those of similar age.
Rachel John, a masters student studying animal behaviour at the University of Exeter, said: 'This population of whales has been formally studied for 50 years – the best-studied orcas on the planet – and yet major new discoveries can still be made.
'We hadn't noticed 'allokelping' before because the videos being collected from our previous aircraft weren't of high enough quality, but the footage we're getting now shows this behaviour in great detail.'
Commenting on the possible reasons for allokelping, Professor Darren Croft, of the University of Exeter and CWR's executive director, said: 'We know touch is really important.
'In primates – including humans – touch moderates stress and helps to build relationships.
'We know killer whales often make contact with other members of their group – touching with their bodies and fins – but using kelp like this might enhance this experience.
'It might also be important for skin health. Whales and dolphins have a variety of strategies to help them slough dead skin, and this may be yet another adaptation for this purpose.
'Brown algaes like bull kelp also have antibacterial and anti-inflammatory properties that may provide further benefits to the whales.'
Professor Croft said researchers were working to confirm the initial findings and 'investigate the social and skin health benefits of this behaviour'.
Other orcas are known to rub their bodies on smooth stone beaches, possibly to remove dead skin and parasites, but the southern resident whales have not been seen doing this.
Funders of the study included the UK Natural Environment Research Council and the Orca Fund, a grant making fund created by Wild Fish Conservancy and administered by the Rose Foundation for Communities and the Environment.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Pump the Brakes on E-Bikes
Pump the Brakes on E-Bikes

Wall Street Journal

time2 hours ago

  • Wall Street Journal

Pump the Brakes on E-Bikes

I applaud the efforts in New York City to adopt an e-bike speed limit of 15 miles per hour, paralleling safety actions abroad ('New York Has a New E-Bike Speed Limit—and Can't Enforce It,' Page One, Aug. 8). Scientific literature from Europe, Asia and the Middle East documents the severe neurosurgical, orthopedic, maxillofacial and other traumatic injuries associated with the higher rate of speed for e-bikes compared to traditional pedal bicycles. The U.S. should learn from this experience and spare the public repeated tragedies. New York can continue to lead the way by implementing new requirements for licensure and registration for those e-bikes that travel at higher speeds more closely resembling mopeds and motorcycles. This will enable law enforcement to identify these vehicles in traffic flow and restrict their use to the roadway instead of bike lanes and sidewalks, where they are more likely to collide with pedestrians in densely populated areas.

Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns

Yahoo

time3 hours ago

  • Yahoo

Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns

Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store